BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jun E, Kim SC, Song KB, Hwang DW, Lee JH, Shin SH, Hong SM, Park K, Lee Y. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute. Surgery 2017;162:120-30. [DOI: 10.1016/j.surg.2017.01.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncol Ther 2022. [PMID: 36136274 DOI: 10.1007/s40487-022-00208-1] [Reference Citation Analysis]
2 Guo X, Gao S, Li Z, Hao J. The role of biomarker in pancreatic neuroendocrine tumor: a narrative review. Journal of Pancreatology 2021;Publish Ahead of Print. [DOI: 10.1097/jp9.0000000000000076] [Reference Citation Analysis]
3 Yu F, Fu J, Zhang C, Wu W, Ai S, Yao X, Meng Q, Huang Y, Lu G, Wang F, Qu W. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms. Pancreas 2021;50:882-9. [PMID: 34347728 DOI: 10.1097/MPA.0000000000001852] [Reference Citation Analysis]
4 Hong L, Wang Y, Zhang T, Zhang C, Wang L, Wang L, Wang Z, Zhong J. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population. Med Sci Monit 2020;26:e926635. [PMID: 33141811 DOI: 10.12659/MSM.926635] [Reference Citation Analysis]
5 Mehta R, Lam-Chung CE, Hinojosa-Amaya JM, Roldán-Sarmiento P, Guillen-Placencia MF, Villanueva-Rodriguez G, Juarez-Leon OA, Leon-Domínguez J, Grajales-Gómez M, Ventura-Gallegos JL, León-Suárez A, Gómez-Pérez FJ, Cuevas-Ramos D. High Molecular Weight ACTH-Precursor Presence in a Metastatic Pancreatic Neuroendocrine Tumor Causing Severe Ectopic Cushing's Syndrome: A Case Report. Front Endocrinol (Lausanne) 2020;11:557. [PMID: 32903471 DOI: 10.3389/fendo.2020.00557] [Reference Citation Analysis]
6 Touitou Y, Lambrozo J, Mauvieux B, Riedel M. Evaluation in humans of ELF-EMF exposure on chromogranin A, a marker of neuroendocrine tumors and stress. Chronobiol Int 2020;37:60-7. [PMID: 31682468 DOI: 10.1080/07420528.2019.1683857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Bresciani G, Hofland LJ, Dogan F, Giamas G, Gagliano T, Zatelli MC. Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line. Front Endocrinol (Lausanne) 2019;10:682. [PMID: 31636608 DOI: 10.3389/fendo.2019.00682] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
8 Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B, Corti A, Falconi M. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). Pancreatology 2019;19:57-63. [DOI: 10.1016/j.pan.2018.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
9 Zhang C, Huang Y, Long J, Yao X, Wang J, Zang S, Qu W, Wang F. Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression. Oncol Lett 2019;17:1497-504. [PMID: 30675205 DOI: 10.3892/ol.2018.9795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Zhuge X, Guo C, Chen Y, Feng L, Jia R, Zhao Y, Sun K, Wang Z, Chen X. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. Pancreas 2018;47:1290-5. [DOI: 10.1097/mpa.0000000000001181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
11 Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2019;21:612-618. [PMID: 30366884 DOI: 10.1016/j.hpb.2018.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
12 Fuksiewicz M, Kowalska M, Kolasińska-Ćwikła A, Ćwikła JB, Sawicki Ł, Roszkowska-Purska K, Drygiel J, Kotowicz B. Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine. Endocr Connect 2018;7:803-10. [PMID: 29724794 DOI: 10.1530/EC-18-0059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
13 Gorelik M, Ahmad M, Grossman D, Grossman M, Cooperman AM. Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors. Surgical Clinics of North America 2018;98:157-67. [DOI: 10.1016/j.suc.2017.09.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
14 Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 49] [Cited by in F6Publishing: 67] [Article Influence: 12.3] [Reference Citation Analysis]
15 Borges R, Gandía L, Carbone E. Old and emerging concepts on adrenal chromaffin cell stimulus-secretion coupling. Pflugers Arch 2018;470:1-6. [PMID: 29110079 DOI: 10.1007/s00424-017-2082-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]